Update on chemoprevention of prostate cancer

Current Opinion in Urology

Volumn 14, Issue 3, 2004, Pages 143-149

  Klein, Eric A ^a,c   Thompson, Ian M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NONE   (United States)

Author keywords

Chemoprevention; Finasteride; Lycopene; Prevention; Prostate cancer; Selenium; Soy; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANDROSTANOLONE; ANTIOXIDANT; BICALUTAMIDE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DUTASTERIDE; FINASTERIDE; LYCOPENE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; SELENIUM; SELENOMETHIONINE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TRACE ELEMENT; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; LEGUME; MALE; MALE SEXUAL DYSFUNCTION; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SOYBEAN; TEA; ULTRAVIOLET RADIATION; UPREGULATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 2342626088     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200405000-00002     Document Type: Review

References (42)

1. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224. This landmark paper describes the findings of the first large-scale US National Cancer Institute-funded prostate cancer prevention effort in the United States. The results demonstrate the willingness and ability of men at risk for prostate cancer to enrol in and complete a 7-year study and obtain meaningful results.
2. Scardino PT. The prevention of prostate cancer: the dilemma continues. N Engl J Med 2003; 349:297-299. This editorial accompanying the publication of the PCPT urges caution in its interpretation.
3. Thompson I, Klein EA, Lippman SM. Prevention of prostate cancer with finasteride: A U.S./European perspective. Eur Urol 2003; 44:650-655.
4. Klein EA. Selenium: epidemiology and basic science. J Urol 2004; 171 (2 Pt 2): S50-53
5. Vogt TM, Ziegler RG, Graubard BI, et al. Serum Se and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 2003; 103:664-670.
6. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Se supplementation, baseline plasma Se status, and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer study group. BJU Int 2003; 91:608-612. This is a follow-up report of the initial randomized, blinded, placebo-controled trial comparing the effects of 200 μg yeast with placebo on the effect of non-melanoma skin cancer recurrence.
7. van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003; 12:866-871. This describes an illustrative epidemiologic study on the risk reduction associated with high levels of selenium.
8. Dewailly E, Mulvad G, Sloth Pedersen H, et al. Inuit are protected against prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:926-927.
9. Dong Y, Zhang H, Hawthorne L, et al. Delineation of the molecular basis for Se-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003; 63:52-59. This article builds on previous work demonstrating that selenium acts early in carcinogenesis to prevent clonal expansion of nascent tumors by blocking cell proliferation and promoting cell death, and that its effects are mediated by a variety of well-defined molecular pathways.
10. Zhao H, Whitfield ML, Xu T, et al. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 2004; 15:506-519. This study confirmed previous observations on the effect of selenium on cell cycling, and demonstrated for the first time that selenium acts as an antiandrogen and induces antioxidant enzymes. The results suggest that the protective effect of selenium are mediated by several different pathways.
11. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caapases in human prostate cancer cells. Cancer Res 2003; 63:6988-6995. This study demonstrated synergy of vitamin E and selenium against cell proliferation in prostate cancer cell lines, primarily by augmentation of apoptosis.
12. Waters DJ, Shen S, Cooley DM, et al. Effects of dietary Se supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 2003; 95:237-241. This placebo-controlled trial demonstrated that important antioxidant effects of oral selenium are measurable in the prostate in an in-vivo canine model, serving as an important proof-of-principle study for the use of selenium in prevention of prostate cancer.
13. Gianduzzo TR, Holmes EG, Tinggi U, et al. Prostatic and peripheral blood selenium levels after oral supplementation. J Urol 2003; 170:870-873. This study demonstrated that oral selenium is concentrated in the prostate.
14. Bhamre S, Whitin JC, Cohen HJ. Selonomethionine does not affect PSA secretion independent of its effect on LNCap growth. Prostate 2003; 54:315-321. This describes an important observation that selenium does not affect PSA secretion, suggesting that selenium use in human trials will not require adjustment of PSA values in deciding on the need for prostate biopsy (unlike what was required for finasteride in the PCPT).
15. Stratton MS, Reid ME, Schwartzberg G, et al. Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study. Anticancer Drugs 2003; 14:589-594.
16. Stratton MS, Reid ME, Schwartzberg G, et al. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study. Anticancer Drugs 2003; 14:595-600.
17. Ni J, Chen M, Zhang Y, et al. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003; 300:357-363. This study demonstrated the effects of vitamin E succinate on cell cycle arrest in prostate cancer cell lines, identified which molecular pathways are modulated, and suggested synergism with selenium in inhibiting cellular proliferation.
18. Thompson TA, Wilding G. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol, in human prostate carcinoma cells. Mol Cancer Ther 2003; 2:797-803. This study demonstrated a potent antiandrogen effect for vitamin E, adding to the list of potential mechanisms by which vitamin E inhibits prostate cancer.
19. Virtamo J, Pietinen P, Huttunen JK, et al. ATBC Study Group: Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003; 290:476-485. This study reported long-term post-intervention effects of β-carotene and α-tocopherol on cancer incidence, cause-specific mortality, and overall mortality in men on the ATBC trial.
20. Goodman GE, Schaffer S, Omenn GS, et al. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003; 12:518-526. This study suggested that both the beneficial and deleterious effects of oral supplements disappear after they are no longer ingested, raising interesting questions on the molecular mechanisms underlying their effects and the best way to provide beneficial supplements to the population at large.
21. Huang HY, Alberg AJ, Norkus EP, et al. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 2003; 157:335-344. This describes one of several studies causing controversy over whether γ-tocopherol is more active in preventing prostate cancer than α-tocopherol. This finding has not been replicated in the ATBC trial or in several other studies.
22. Klein EA, Thompson IM, Lippman SM, et al. The Selenium and Vitamin E Cancer Prevention Trial. World J Urol 2003; 21:21-27. This article is an overview of the epidemiologic and biologic data supporting the use of selenium and vitamin E as preventative agents and the design assumptions of the Selenium and Vitamin E Cancer Prevention Trial.
23. Peehl DM, Krishnan AV, Feldman D. Pathways modeling the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003; 133 (Suppl 7):2461S-2469S. These authors provide a nice summary of the epidemiologic data supporting the hypothesis that vitamin D deficiency is associated with prostate cancer risk, as well as an overview of molecular mechanisms potentialy underlying its action.
24. Bodiwala D, Luscombe CJ, French ME, et al. Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis 2003; 24:711-717.
25. Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 2003; 12:597-603. This was a well-designed prospective study examining dietary dairy and calcium intake and the risk of prostate cancer.
26. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003; 68:363-371. This is an excelent overview of the molecular targets of vitamin D in prostate cancer, highlighting the role of insulin-like growth factor binding protein 1.
27. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 2003; 169:2352-2359. This is an excellent overview of the pathogenesis of COX-2 in urological cancers and the rationale for COX-2 inhibitors in prevention and therapy.
28. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003; 191:125-135.
29. Pan Y, Zhang JS, Gazi MH, Young CY. The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2003; 12:769-774. This describes the first observation that COX-2 inhibitors have direct antiandrogenic effects.
30. Shappell SB, Olson SJ, Hannah SE, et al. Bevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 2003; 63:2256-2267. This interesting study suggested selective expression of COX-2 in precursor lesions of prostate cancer, establishing an excellent model system for studying COX-2 inhibition as a preventative strategy.
31. Lee MM, Gomez SL, Chang JS, et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003; 12:665-668. This well-done study demonstrated the protective effect of diets high in soy on the risk of prostate cancer even in a low-risk country like China. This study raises interesting questions about dietary and environmental interactions.
32. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equal modulates the growth of benign and malignant prostate epithelial cells in vitro. Prostate 2003; 54:68-78.
33. Cohen LA, Zhao Z, Pittman B, Scimeca J. Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. Prostate 2003; 54:169-180.
34. Yu L, Blackburn GL, Zhou JR. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr 2003; 133:389-392. This study demonstrated a potential antiandrogenic effect for the major isoflavones found in soy.
35. Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-1-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr 2003; 133:2367-2376. Insulin-like growth factor I is a known risk factor for prosate cancer in humans, and this article suggests that the polyphenols in soy and tomato products may be effective in inhibiting its action.
36. Kazi A, Daniel KG, Smith DM, et al. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003; 66:965-976.
37. Jenkins DJ, Kendall CW, D'Costa MA, et al. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. J Urol 2003; 169:507-511. This was one of the few studies to look at the effect of soy on serum PSA levels, which surprisingly did not change despite the known estrogenic effects of these compounds.
38. Obermuller-Jevic UC, Olano-Martin E, et al. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 2003; 133:3356-3360.
39. Boilesu TW, Liao Z, Kim S, et al. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003; 95:1578-1586. This study illustrated the effect of caloric restriction and dietary supplementation on risk of dying from prostate cancer in a mice model, and highlights differential effects of whole foods versus individual dietary supplements.
40. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003; 133 (Suppl 7):2417S-2424S.
41. Hastak K, Gupta S, Ahmad N, et al. Role of p63 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003; 22:4851-4859. This is a dissection of the molecular effects of the major polyphenol in green tea.
42. Brusselmans K, De Schrijver E, Heyns W, et al. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 2003; 108:856-862. This article suggests a novel mechanism for the antiapoptotic effect of EGCG, involving fatty acid synthase, a known marker for progression for prostate cancer.